Search results for "immunoglobulin G"

showing 10 items of 308 documents

Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization

2022

Abstract Aims Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has had a serious worldwide impact on human health. On December 2020, an immunization campaign with a COVID-19 mRNA vaccine (Comirnaty-BNT162b2 Pfizer-BioNTech) was started in Italy, first targeting healthcare workers (HCWs). This study aims to investigate the antibodies that are response against SARS-CoV-2 vaccine. Methods and Results The kinetics and the persistence of both anti-S1/S2 IgGs and neutralizing antibodies (Nt-Abs) were investigated in 76 HCWs through a 4-month follow-up with multiple testing points starting at the first dose. Temporal analysis of SARS-CoV-2 Abs titre kinetics showed three diff…

Settore MED/07 - Microbiologia E Microbiologia ClinicaVaccines SyntheticCOVID-19 VaccinesSARS-CoV-2VaccinationCOVID-19General Medicineneutralizing antibodies.Settore MED/42 - Igiene Generale E ApplicataAntibodies ViralAntibodies NeutralizingApplied Microbiology and BiotechnologyKineticsItalyhealthcare workerImmunoglobulin GSpike Glycoprotein CoronavirusHumansmRNA Vaccineskinetics of antibodieBNT162 VaccineBiotechnologyJournal of Applied Microbiology
researchProduct

Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS‐CoV‐2 neutralizing activity of sera

2020

Purpose: Assessment of commercial SARS-CoV-2 immunoassays for their capacity to provide reliable information on sera neutralizing activity is an emerging need. We evaluated the performance of two commercially-available lateral flow immunochromatographic assays (LFIC) (Wondfo SARS-CoV-2 Antibody test and the INNOVITA 2019-nCoV Ab test) in comparison with a SARS-CoV-2 neutralization pseudotyped assay for COVID-19 diagnosis in hospitalized patients, and investigate whether the intensity of the test band in LFIC associates with neutralizing antibody (NtAb) titers. Patients and Methods: Ninety sera were included from 51 patients with moderate to severe COVID-19. A green fluorescent protein (GFP)…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Green Fluorescent ProteinsAntibodies ViralNeutralizing antibodiesNeutralizationSARS‐CoV‐2Green fluorescent protein03 medical and health sciencesCOVID-19 Testing0302 clinical medicineCOVID‐19VirologyLateral flow 16 immunochromatographic assaysHumansMedicineImmunochromatographic Assays030212 general & internal medicineNeutralizing antibodyResearch ArticlesImmunoassaybiologybusiness.industrySARS-CoV-2COVID-19biology.organism_classificationAntibodies NeutralizingVirologyTiterInfectious DiseasesImmunoglobulin MVesicular stomatitis virusImmunoglobulin GSpike Glycoprotein Coronavirusbiology.proteinlateral flow immunochromatographic assays030211 gastroenterology & hepatologyLteral flow immunochromatographic assaysAntibodybusinessResearch Article
researchProduct

Clinical manifestations of the anti-IgLON5 disease

2017

Objective:To report the presentation, main syndromes, human leukocyte antigen (HLA) association, and immunoglobulin G (IgG) subclass in the anti-IgLON5 disease: a disorder with parasomnias, sleep apnea, and IgLON5 antibodies.Methods:This was a retrospective clinical analysis of 22 patients. The IgG subclass was determined using reported techniques.Results:Patients' median age was 64 years (range 46–83). Symptoms that led to initial consultation included sleep problems (8 patients; 36%), gait abnormalities (8; 36%), bulbar dysfunction (3; 14%), chorea (2; 9%), and cognitive decline (1; 5%). By the time of diagnosis of the disorder, 4 syndromes were identified: (1) a sleep disorder with paras…

Sleep Wake Disorders0301 basic medicinemedicine.medical_specialtyCell Adhesion Molecules NeuronalPopulationExcessive daytime sleepinessAutoimmune DiseasesProgressive supranuclear palsy03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCognitive declineeducationAgedAutoantibodiesRetrospective StudiesAged 80 and overeducation.field_of_studySleep disorderbusiness.industryBrainSleep apneaChoreaParasomniaMiddle Agedmedicine.disease030104 developmental biologyImmunoglobulin GImmunotherapyNeurology (clinical)medicine.symptomCarrier ProteinsbusinessBiomarkers030217 neurology & neurosurgeryHLA-DRB1 ChainsNeurology
researchProduct

4-4-20 anti-fluorescyl IgG Fab' recognition of membrane bound hapten: direct evidence for the role of protein and interfacial structure.

1995

The surface forces apparatus was used to identify the molecular forces that control the interactions of monoclonal 4-4-20 antifluorescyl IgG Fab' fragments with fluorescein-presenting supported planar bilayers. At long range, the electrostatic force between oriented Fab' and fluorescein monolayers was controlled by the composition of the protein exterior surrounding the antigen-combining site rather than by the overall protein charge. The measured positive electrostatic potential of the Fab' monolayer at pH > pI(Fab') was consistent with the structure of the exposed Fab' surface in which a ring of positive charge at the mouth of the antigen-combining site dominates the local electrostatic s…

Steric effectsProtein DenaturationChemistryStereochemistryProtein ConformationSurface PropertiesCell MembraneAntibodies MonoclonalSurface forces apparatusAdhesionFluoresceinsBiochemistryProtein–protein interactionAntigen-Antibody ReactionsImmunoglobulin Fab FragmentsMembraneProtein structureImmunoglobulin GMonolayerBiophysicsElectrochemistryFluoresceinHaptenHaptensBiochemistry
researchProduct

Uptake of Leishmania major by dendritic cells is mediated by Fcγ receptors and facilitates acquisition of protective immunity

2006

Uptake of Leishmania major by dendritic cells (DCs) results in activation and interleukin (IL)-12 release. Infected DCs efficiently stimulate CD4- and CD8- T cells and vaccinate against leishmaniasis. In contrast, complement receptor 3-dependent phagocytosis of L. major by macrophages (MPhi) leads exclusively to MHC class II-restricted antigen presentation to primed, but not naive, T cells, and no IL-12 production. Herein, we demonstrate that uptake of L. major by DCs required parasite-reactive immunoglobulin (Ig)G and involved FcgammaRI and FcgammaRIII. In vivo, DC infiltration of L. major-infected skin lesions coincided with the appearance of antibodies in sera. Skin of infected B cell-de…

T cellImmunologyAntigen presentationLeishmaniasis CutaneousMacrophage-1 AntigenPriming (immunology)Complement receptorArticleImmunoglobulin GMicePhagocytosismedicineAnimalsImmunology and AllergyLeishmania majorCells CulturedLeishmania majorMice KnockoutB-LymphocytesMice Inbred BALB CbiologyMacrophagesReceptors IgGArticlesDendritic Cellsbiology.organism_classificationMice Inbred C57BLmedicine.anatomical_structureImmunoglobulin GImmunologybiology.proteinInterleukin 12CD8Journal of Experimental Medicine
researchProduct

Thymoma and paraneoplastic myasthenia gravis

2010

Paraneoplastic autoimmune diseases associate occasionally with small cell lung cancers and gynecologic tumors. However, myasthenia gravis (MG) occurs in at least 30% of all patients with thymomas (usually present at MG diagnosis). These epithelial neoplasms almost always have numerous admixed maturing polyclonal T cells (thymocytes). This thymopoiesis-and export of mature CD4(+)T cells-particularly associates with MG, though there are rare/puzzling exceptions in apparently pure epithelial WHO type A thymomas. Other features potentially leading to inefficient self-tolerance induction include defective epithelial expression of the autoimmune regulator (AIRE) gene and/or of major histocompatib…

ThymomaThymomaT-LymphocytesGenes MHC Class IIImmunologyCellThymus Glandmedicine.disease_causeAutoantigensAutoimmunityhemic and lymphatic diseasesMyasthenia GravisHumansImmunology and AllergyMedicineLymphopoiesisPolyendocrinopathies AutoimmuneAutoantibodiesMHC class IIbiologybusiness.industryLymphopoiesisFOXP3Epithelial Cellsmedicine.diseaseAutoimmune regulatorMyasthenia gravismedicine.anatomical_structureImmunoglobulin GImmunologybiology.proteinbusinessParaneoplastic Syndromes Nervous SystemTranscription FactorsAutoimmunity
researchProduct

A lethal Tick-Borne Encephalitis (TBE) due to TBE virus in Sicily (Italy): A case of IgG+/IgM-response?

2018

Tick-borne encephalitis (TBE) is an important viral infection of the central nervous system with high morbidity and mortality. With the increase of tourism TBE is becoming a problem also outside endemic regions. Italy is considered a country with low incidence of TBE and geographically restricted to the central and north eastern part of the country. In the south of Italy there is no evidence of disease presence, but neither is there much evidence of its absence. We report our experience about a lethal case of meningoencephalitis with a single-phase clinical course of the disease likely due to TBEV infection in a 13-year-old man. This is the first report of an autochthonous case of TBE in Si…

Tick-BorneTick-borne encephalitiMaleAdolescentAnimalMedicine (all)IncidenceEncephalitis Viruses Tick-BorneEncephalitis VirusesImmunoglobulin MFatal caseImmunoglobulin GFatal case; Ig-M negative; TBEV in Sicily; Tick-borne encephalitis; Adolescent; Animals; Encephalitis Viruses Tick-Borne; Encephalitis Tick-Borne; Humans; Immunoglobulin G; Immunoglobulin M; Incidence; Male; Sicily; Medicine (all)Tick-borne encephalitisEncephalitisAnimalsHumansIg-M negativeTBEV in SicilySicilyEncephalitis Tick-BorneHuman
researchProduct

IMMUNOGENICITY OF AN ACELLULAR PERTUSSIS VACCINE COMPOSED OF GENETICALLY INACTIVATED PERTUSSIS TOXIN COMBINED WITH FILAMENTOUS HEMAGGLUTININ AND PERT…

1993

We studied the immunogenicity of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin, and a 69-kilodalton protein, pertactin, in 30 children aged 12 to 24 months and in 80 infants aged 2 to 4 months. A significant increase of the neutralizing titer and of the titers against pertussis toxin, filamentous hemagglutinin, and pertactin, as determined by enzyme-linked immunosorbent assay, was achieved after three doses of vaccine in all the children; a significant increase of these antibody titers was obtained in 100%, 96.1%, 93.5%, and 98.7% of the infants, respectively.

Time FactorsFilamentous haemagglutinin adhesinPertussis toxincomplex mixturesBordetella pertussisMicrobiologyNeutralization TestsHumansMedicineVirulence Factors BordetellaAdhesins BacterialImmunization ScheduleWhooping coughPertussis VaccineAntigens Bacterialbusiness.industryImmunogenicitypertussisAntibody titerInfantmedicine.diseaseAntibodies BacterialVirologyVaccinationTiterHemagglutininsPertussis ToxinVaccines InactivatedChild PreschoolImmunoglobulin GPediatrics Perinatology and Child HealthDrug EvaluationPertactinbusinessVaccinepertussis; VaccineBacterial Outer Membrane Proteins
researchProduct

Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.

2004

1. A study performed > 10 years ago and case reports published recently suggest that triclabendazole is effective for the treatment of patients with fascioliasis. 2. To confirm the efficacy of a human formulation of triclabendazole, we enrolled 165 patients into the present study and divided the subjects into two groups: (i) those who had fascioliasis, as evidenced by the presence of ova in their stools; and (ii) patients with clinical and laboratory data suggesting fascioliasis. 3. Patients were randomly allocated to receive 10 mg/kg, p.o., triclabendazole for 1, 2 or 3 days (single-, double- and triple-dose groups, respectively). Medical history and physical and laboratory examinations we…

Toxic hepatitisAdultMalemedicine.medical_specialtyCure rateFascioliasisAdolescentPhysiologyChemistry PharmaceuticalGastroenterologylaw.inventionFecesRandomized controlled triallawOral administrationPhysiology (medical)Internal medicineMedicineHumansMedical historyIn patientChildTriclabendazoleAgedPharmacologyAnthelminticsDose-Response Relationship Drugbusiness.industryMiddle AgedSurgeryTriclabendazoleTreatment OutcomeHuman fascioliasisImmunoglobulin GBenzimidazolesFemalemedicine.symptombusinessmedicine.drugClinical and experimental pharmacologyphysiology
researchProduct

Detection of anti-myeloperoxidase antibodies in the serum of patients with type 1 diabetes mellitus.

1996

Anti-myeloperoxidase (anti-MPO) antibodies were detected in 34 of 88 (38%) patients with type 1 diabetes mellitus but in only 3 of 55 (5.7%) healthy subjects and in 4 of 20 patients with autoimmune disease. Specificity of anti-MPO antibodies was assessed by MPO inhibition studies. No relationship was found between the occurrence of anti-MPO and anti-thyroperoxidase antibodies. Levels of soluble intercellular adhesion molecule 1 (ICAM-1) were found to be higher in anti-MPO antibody-positive (n = 28, 508 +/- 126 ng/ml) than in anti-MPO antibody-negative (n = 58, 438 +/- 140 ng/ml: P < 0.05) patients. A state of chronic neutrophil activation has been described in diabetes mellitus. As anti-MPO…

Vasculitismedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismDiabetic angiopathyMonoclonal antibodyIodide PeroxidaseAntibodies Antineutrophil CytoplasmicEndocrinologyDiabetes mellitusInternal medicineInternal MedicineMedicineHumansChildFluorescent Antibody Technique IndirectAutoantibodiesPeroxidaseAutoimmune diseaseType 1 diabetesbiologybusiness.industryGeneral Medicinemedicine.diseaseIntercellular Adhesion Molecule-1EndocrinologyDiabetes Mellitus Type 1MyeloperoxidaseChild PreschoolImmunoglobulin Gbiology.proteinAntibodybusinessSystemic vasculitisActa diabetologica
researchProduct